Table 7. In Vivo Therapeutic Effect of 36 (AMX12006) in Combination with Capecitabine in CT-26 BALB/c Mouse Xenograftsa.
| group (n) | treatment | mode of treatment | mean tumor vol., TV (mm3) | TGI (%) |
|---|---|---|---|---|
| G1 (6) | vehicle | po, qd | 2036.95 ± 333.12 | b |
| G2 (6) | capecitabine (300 mg/kg) | po, qd | 707.13 ± 124.69 | 67.88 |
| G3 (6) | AMX12006 (75 mg/kg) + capecitabine (300 mg/kg) | po, qd | 688.04 ± 177.96 | 68.85 |
| G4 (6) | AMX12006 (150 mg/kg) + capecitabine (300 mg/kg) | po, qd | 190.24 ± 53.87 | 94.26 |
a
po, oral dosing; qd, administered every day; vehicle, 0.5% carboxymethyl-cellulose sodium. The animals were administered the doses starting from the 8th day after tumor implantation and continuing until 21 days and sacrificed on the same day; n = number of animals in each group.
b
Not applicable.